BFC Planning’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
BFC Planning's VRDN Position: Q3 2026 in Review
BFC Planning held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 29 shares worth $597. The position accounts for ﹤0.01% of the portfolio, ranked #3265.
BFC Planning first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- BFC Planning held 29 shares of Viridian Therapeutics worth $597 as of Q3 2026.
- BFC Planning left its Viridian Therapeutics share count unchanged in Q3 2026.
- Viridian Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3265 holding.
- BFC Planning first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.